SecBot SecBot
Insider Cluster (5 insiders) ·Filed Aug 14, 2026

EWTX

Edgewise Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago
Insider cluster: 5 insiders, $0.4M total
Actionable Insight • Neutral

The insider sales are routine and likely tax-related from vesting grants. The real catalyst is the company's pivot to cardiovascular with EDG-7500 Phase 3 starting Q4 2026 and a $2.01B cash position. Monitor for Phase 3 enrollment updates and any further insider selling that deviates from this pattern.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

EWTX drug pipeline →

EDG-7500

◆ Mixed Named in this insider cluster
Impact
Phase
Phase 2
Time to market
4-6 years (Phase 2 completed; Phase 3 starting Q4 2026; if successful, NDA filing likely 2029-2030 at earliest)
Next catalyst
None dated

What to watchEdgewise is now a cardiovascular-focused single-product company after selling its muscular dystrophy business to Servier for $1.55B upfront. EDG-7500's Phase 2 safety data (no LVEF drops below 50% across all patients) is a genuine differentiator, but efficacy against BMS's approved Camzyos and Cytokinetics' pending aficamten remains unproven. Watch for Phase 3 start in Q4 2026 and any partnership/BD rumors for the program.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$44.04
T+0 close · Aug 14, 2026 · via day close
Latest settled
+5.65%
T+60 · $46.53
Vs SPY
+8.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $44.04entry
  2. T+1 · 3mo ago +0.16%α +0.83% · $44.11
  3. T+5 · 3mo ago +1.54%α +2.73% · $44.72
  4. T+20 · 2mo ago −0.93%α +1.05% · $43.63
  5. T+60 · 7d ago +5.65%α +8.60% · $46.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Five C-suite insiders at Edgewise Therapeutics sold a total of ~$401K in open-market shares on August 12, 2026, following the company's Q2 earnings miss and the transformative sevasemten sale to Servier. The sales are small relative to the $4.8B market cap (0.008%), but the cluster of all top executives selling on the same day after a major corporate pivot warrants attention. The non-cash grants and derivative exercises on the same date suggest these sales are likely liquidity-driven to cover tax obligations from vesting, not a bearish signal on the company's cardiovascular-focused future.

Key Financial Metrics

Direction
selling
Total Value
$401.0K
Insiders
5

Key Facts

  • Five C-suite insiders (CEO, CFO, CMO, CSO, CBO) sold shares on August 12, 2026
  • Total open-market sales: ~$401K, or 0.008% of $4.8B market cap
  • Sales occurred 6 days after Q2 2026 earnings miss ($0.53 loss vs $0.47 consensus) and the $1.55B sevasemten sale to Servier
  • All insiders also received large non-cash stock grants and exercised derivatives on the same date, indicating tax-withholding sales
  • The cluster is small in dollar terms and likely driven by vesting schedules, not a coordinated bearish view

Financial Impact

Total insider sales of ~$401K, immaterial relative to $4.8B market cap

insider ownershipdilution

Risk Factors

  • Insider sales could accelerate if stock rallies on pipeline news
  • Pre-revenue company with widening operating losses; cash burn may accelerate as Phase 3 begins
  • Any delay in Phase 3 start or negative data would be highly bearish

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
84% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-EWTX-1787007679886

Track record

14 reports on EWTX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today 144 Neutral 1/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  4. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
  6. Aug 14, 202613w ago Insider Cluster Neutral 4/10 Viewing Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  7. Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
  9. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
  10. Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (10h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026